Journal Basic Info

  • Impact Factor: 1.989**
  • H-Index: 6
  • ISSN: 2637-4625
  • DOI: 10.25107/2637-4625
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Bariatric Surgery
  •  Minimal Invasive Surgery
  •  Ophthalmology
  •  Obstetrics & Gynecology
  •  Endocrine Surgery
  •  Anesthesiology
  •  Orthopaedic Surgery
  •  Reconstructive Surgery


Citation: World J Surg Surg Res. 2022;5(1):1369.DOI: 10.25107/2637-4625.1369

Safety and Efficacy Evaluation of MSLN-Chimeric Antigen Receptor T Cells Secreting Anti-PD-1 Antibodies in the Treatment of Advanced Metastatic Cancers

Yong Xia1#, Faliang Zhang1,2,3#, Pei Wang5#, Xinhong Guan1#, Xue Wang1 , Shenglan Lai1 , Hui Xue1 , Yanyan Yu1 , Zongchang Song1 *, Jinxing Lou1,2,3* and Qijun Qian1,4,5*

1 Department of Oncology, Shanghai University Affiliated Mengchao Cancer Hospital, China 2 Department of Oncology, Ningbo 5th Hospital (Ningbo Cancer Hospital), China 3 Department of Oncology, Suzhou BenQ Hospital, China 4 Shanghai Cell Therapy Research Institute, China 5 Shanghai Cell Therapy Group, China # These authors contributed equally to this work

*Correspondance to: Jinxing Lou 

 PDF  Full Text Research Article | Open Access


Objectives: Although Chimeric Antigen Receptor T (CAR-T) cells exhibit a potent therapeutic effect in B-lineage hematologic malignancies, CAR-T therapy for the heterogeneous solid tumors remains challenging. Tumor immunosuppressive micro-environment within the solid tumor may inhibit the activities of the CAR-T cells. To overcome this obstacle, we generated -MSLN-CAR-T cells secreting anti-Programmed cell Death-1 (PD-1) antibodies (αPD-1-MSLN-CAR-T cells) based piggyBac transposon system and performed a pilot study to assess the safety and efficacy of αPD-1- MSLN-CAR-T cells in the treatment of advanced metastatic malignancies. Methods: An exploratory multicenter clinical trial was conducted from July 2018 to July 2019. Advanced patients over-expressed with Mesothelin (MSLN) and Programmed Death-Ligand 1 (PD-L1) received one cycles of αPD-1-MSLN-CAR-T cells with a cell dose of 2 × 106 cells/kg. Nine patients were recruited in this study who met the requirements of the clinical trial. Safety and progression-free survival were the primary endpoints and overall survival was the secondary endpoint. Results: Amongst the 9 cases that participated in the study, 2 cases exhibited a partial remission, and 4 cases achieved stable disease after cell transfusion. The median progression-free survival and overall survival were 4.2 months (95% CI, 2.7–5.7 months) and 6.5 months (95% CI, 4.7–8.3 months), respectively. One case developed fever and Cytokine Release Syndrome (CRS) (grade 1). Most cases had grade 3/4 decreases in lymphocyte counts. Conclusion: Our data primarily indicate that αPD-1-MSLN- CAR-T cell therapy exhibits a demonstrated effect in advanced metastatic malignancies with low toxicities.


Mesothelin; Chimeric antigen receptor; Immunotherapy; PD-1; Malignancy

Cite the Article:

Xia Y, Zhang F, Wang P, Guan X, Wang X, Lai S, et al. Safety and Efficacy Evaluation of MSLN-Chimeric Antigen Receptor T Cells Secreting AntiPD-1 Antibodies in the Treatment of Advanced Metastatic Cancers. World J Surg Surgical Res. 2022;5:1369..

Search Our Journal

Journal Indexed In

Articles with Grants

Clinical Summary and Score System of 91 Cases of Cerebellar Hemorrhage
 Abstract  PDF  Full Text
Association of Lymphocytes with the Duration of Survival in Artificially Fed Patients with Dysphagia: A Retrospective Cohort Study
 Abstract  PDF  Full Text
View More...